Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Hims & Hers Health, Inc. or Roivant Sciences Ltd. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Hims & Hers Health, Inc. and Roivant Sciences Ltd. compare based on key financial metrics to determine which better meets your investment needs.

About Hims & Hers Health, Inc. and Roivant Sciences Ltd.

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Latest Health Care Providers & Services and Hims & Hers Health, Inc., Roivant Sciences Ltd. Stock News

As of September 2, 2026, Hims & Hers Health, Inc. had a $6.7 billion market capitalization, compared to the Health Care Providers & Services median of $1.7 million. Hims & Hers Health, Inc.’s stock is down 14.2% in 2026, down 12% in the previous five trading days and down 30.94% in the past year.

Currently, Hims & Hers Health, Inc. does not have a price-earnings ratio. Hims & Hers Health, Inc.’s trailing 12-month revenue is $2.6 billion with a -5.5% net profit margin. Year-over-year quarterly sales growth most recently was 38.3%. Analysts expect adjusted earnings to reach $0.537 per share for the current fiscal year. Hims & Hers Health, Inc. does not currently pay a dividend.

As of September 2, 2026, Roivant Sciences Ltd. had a $24.7 billion market cap, putting it in the 88th percentile of all stocks. Roivant Sciences Ltd.’s stock is up 56.6% in 2026, down 9.6% in the previous five trading days and up 175.87% in the past year.

Currently, Roivant Sciences Ltd. does not have a price-earnings ratio. Roivant Sciences Ltd.’s trailing 12-month revenue is $7.5 million with a % net profit margin. Year-over-year quarterly sales growth most recently was -36.4%. Analysts expect adjusted earnings to reach $-1.580 per share for the current fiscal year. Roivant Sciences Ltd. does not currently pay a dividend.

How We Compare Hims & Hers Health, Inc. and Roivant Sciences Ltd. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Hims & Hers Health, Inc. and Roivant Sciences Ltd.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Hims & Hers Health, Inc. and Roivant Sciences Ltd. Stock Value Grades

Company	Ticker	Value
Hims & Hers Health, Inc.	HIMS	F
Roivant Sciences Ltd.	ROIV	na

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Hims & Hers Health, Inc. has a Value Score of 10, which is Ultra Expensive. Roivant Sciences Ltd. does not have a meaningful Value Score.

The Value Stock Winner: No Clear Winner

Neither Hims & Hers Health, Inc. or Roivant Sciences Ltd. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Hims & Hers Health, Inc. or Roivant Sciences Ltd. is the better investment when it comes to value.

Hims & Hers Health, Inc. and Roivant Sciences Ltd.’s Momentum Grades

Company	Ticker	Momentum
Hims & Hers Health, Inc.	HIMS	D
Roivant Sciences Ltd.	ROIV	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Hims & Hers Health, Inc. has a Momentum Score of 38, which is Weak. Roivant Sciences Ltd. has a Momentum Score of 94, which is Very Strong.

The Momentum Grade Winner: Roivant Sciences Ltd.

As you can clearly see from the Momentum Grade breakdown above, Roivant Sciences Ltd. is considered to have stronger momentum compared to Hims & Hers Health, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Roivant Sciences Ltd. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Hims & Hers Health, Inc. and Roivant Sciences Ltd.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Hims & Hers Health, Inc.	HIMS	D
Roivant Sciences Ltd.	ROIV	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Hims & Hers Health, Inc. has a Earnings Estimate Score of 29, which is Negative. Roivant Sciences Ltd. has a Earnings Estimate Score of 28, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Hims & Hers Health, Inc. or Roivant Sciences Ltd. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Hims & Hers Health, Inc. or Roivant Sciences Ltd. is the better investment when it comes to estimate revisions.

Other Hims & Hers Health, Inc. and Roivant Sciences Ltd. Grades

In addition to Momentum, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Hims & Hers Health, Inc. and Roivant Sciences Ltd. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Hims & Hers Health, Inc. or Roivant Sciences Ltd. Stock?

Overall, Hims & Hers Health, Inc. stock has a Value Score of 10, Momentum Score of 38 and Estimate Revisions Score of 29.

Roivant Sciences Ltd. stock has a Value Score of , Momentum Score of 94 and Estimate Revisions Score of 28.

Comparing Hims & Hers Health, Inc. and Roivant Sciences Ltd.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.